Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06423911 · ClinicalTrials.gov registry record · Phase 3
Study of Olverembatinib (HQP1351) in Patients With CP-CML
A Phase 3 study of Chronic Myeloid Leukemia and CML, sponsored by Ascentage Pharma Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 285
- Enrollment target
- 1
- Study location
NCT06423911 is a Phase 3 study of Chronic Myeloid Leukemia and CML that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 285 participants, above the 202-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (41% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06423911, a Phase 3 study of Chronic Myeloid Leukemia and CML, is actively recruiting participants, sponsored by Ascentage Pharma Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 285 participants
- Enrollment target
- 1
- Study location
Study Summary
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Conditions Studied
Interventions
- DRUG olverembatinib
- DRUG Bosutinib
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2026-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06423911
The ClinicalTrials.gov registry entry for NCT06423911 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 202-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (41% higher). The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which olverembatinib is the first listed.
NCT06423911 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06423911 about?
NCT06423911 is a clinical study titled "Study of Olverembatinib (HQP1351) in Patients With CP-CML". A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
What is the current status of trial NCT06423911?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 285 participants. The study started on 2024-02-05. Estimated completion is 2026-02.
What conditions does trial NCT06423911 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia, CML, CML, Chronic Phase.
What interventions are being tested in trial NCT06423911?
The interventions under investigation include: olverembatinib (DRUG), Bosutinib (DRUG).
Who is sponsoring clinical trial NCT06423911?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06423911 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
RECRUITING · Phase 2
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.